IT8223872A0 - Agente terapeutico a base di oligonucleotide e metodi per laproduzione dello stesso. - Google Patents

Agente terapeutico a base di oligonucleotide e metodi per laproduzione dello stesso.

Info

Publication number
IT8223872A0
IT8223872A0 IT8223872A IT2387282A IT8223872A0 IT 8223872 A0 IT8223872 A0 IT 8223872A0 IT 8223872 A IT8223872 A IT 8223872A IT 2387282 A IT2387282 A IT 2387282A IT 8223872 A0 IT8223872 A0 IT 8223872A0
Authority
IT
Italy
Prior art keywords
oligonucleotide
production
methods
therapeutic agent
agent based
Prior art date
Application number
IT8223872A
Other languages
English (en)
Other versions
IT1206311B (it
Inventor
Richard H Tullis
Original Assignee
Molecular Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23218662&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IT8223872(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Molecular Biosystems Inc filed Critical Molecular Biosystems Inc
Publication of IT8223872A0 publication Critical patent/IT8223872A0/it
Application granted granted Critical
Publication of IT1206311B publication Critical patent/IT1206311B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IT8223872A 1981-10-23 1982-10-22 Agente terapeutico a base di oligonucleotide e metodi per laproduzione dello stesso. IT1206311B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31412481A 1981-10-23 1981-10-23

Publications (2)

Publication Number Publication Date
IT8223872A0 true IT8223872A0 (it) 1982-10-22
IT1206311B IT1206311B (it) 1989-04-14

Family

ID=23218662

Family Applications (1)

Application Number Title Priority Date Filing Date
IT8223872A IT1206311B (it) 1981-10-23 1982-10-22 Agente terapeutico a base di oligonucleotide e metodi per laproduzione dello stesso.

Country Status (12)

Country Link
US (2) US7285537B1 (it)
EP (1) EP0092574B1 (it)
JP (2) JP2547714B2 (it)
AT (1) ATE75483T1 (it)
AU (1) AU568067B2 (it)
CA (1) CA1208147A (it)
DE (1) DE3280400D1 (it)
DK (1) DK288183A (it)
IE (1) IE58009B1 (it)
IL (1) IL67053A (it)
IT (1) IT1206311B (it)
WO (1) WO1983001451A1 (it)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU568067B2 (en) * 1981-10-23 1987-12-17 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and methods of making same
NZ209840A (en) * 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
US5272065A (en) * 1983-10-20 1993-12-21 Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5208149A (en) * 1983-10-20 1993-05-04 The Research Foundation Of State University Of New York Nucleic acid constructs containing stable stem and loop structures
US5190931A (en) * 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
US5580716A (en) * 1985-03-21 1996-12-03 Stephen A. Johnston Parasite-derived resistance
WO1986005516A1 (en) * 1985-03-21 1986-09-25 Duke University Parasite-derived resistance
US4959463A (en) * 1985-10-15 1990-09-25 Genentech, Inc. Intermediates
JPS63501923A (ja) * 1985-12-05 1988-08-04 フレツド　ハツチンソン　キヤンサ−　リサ−チ　センタ− レトロウイルス疾病状態の治療のためのアンチセンスｒｎａ
US5453566A (en) * 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US5194428A (en) * 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5637573A (en) * 1986-05-23 1997-06-10 Agrawal; Sudhir Influenza virus replication inhibiting oligonucleotide analogues and their pharmaceutical compositions
AU613989B2 (en) * 1987-11-24 1991-08-15 Gen-Probe Incorporated Means and method for enhancing nucleic acid hybridization
WO1989005358A1 (en) 1987-11-30 1989-06-15 University Of Iowa Research Foundation Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
ATE137806T1 (de) * 1988-07-05 1996-05-15 Baylor College Medicine Verfahren zur identifizierung von bakterien
US5004810A (en) * 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
FR2687679B1 (fr) * 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
FR2686882B1 (fr) * 1992-02-05 1994-05-06 Centre Nat Rech Scient Oligothionucleotides.
US5633360A (en) * 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5738985A (en) * 1993-04-02 1998-04-14 Ribogene, Inc. Method for selective inactivation of viral replication
US6824976B1 (en) 1993-04-02 2004-11-30 Rigel Pharmaceuticals, Inc. Method for selective inactivation of viral replication
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
US6727230B1 (en) 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
EP1005368B1 (en) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
US7262173B2 (en) * 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
CA2326823A1 (en) 1998-04-20 1999-10-28 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
EP1733735B1 (en) 1998-05-22 2017-03-22 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity
US6887464B1 (en) 1999-02-02 2005-05-03 Biocache Pharmaceuticals, Inc. Advanced antigen presentation platform
US7776343B1 (en) 1999-02-17 2010-08-17 Csl Limited Immunogenic complexes and methods relating thereto
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
EP1322655B1 (en) 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynucleotide and its use to induce an immune response
DK1296714T3 (da) 2000-06-22 2009-12-07 Coley Pharm Gmbh Kombination af CpG og antistoffer, der er rettet mod CD19, CD20, CD22 eller CD40 til behandling eller forebyggelse af kræft
ATE398175T1 (de) 2000-12-08 2008-07-15 Coley Pharmaceuticals Gmbh Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002361468A1 (en) 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
CN1604795B (zh) 2001-08-17 2010-05-26 科勒制药股份公司 具有提高的活性的组合基序免疫刺激寡肽
WO2003027313A2 (en) 2001-09-24 2003-04-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
WO2004012669A2 (en) 2002-08-01 2004-02-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
DK1455593T3 (da) 2001-10-06 2013-08-26 Merial Ltd Fremgangsmåder og sammensætninger til fremme af vækst og medfødt immunitet hos unge dyr
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2003230806B2 (en) 2002-04-04 2009-05-07 Zoetis Belgium S.A. Immunostimulatory G,U-containing oligoribonucleotides
WO2003102011A1 (en) * 2002-05-29 2003-12-11 Neopharm, Inc. Method for determining oligonucleotide concentration
US7704965B2 (en) * 2002-06-26 2010-04-27 The Penn State Research Foundation Methods and materials for treating human papillomavirus infections
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
WO2004033638A2 (en) * 2002-10-07 2004-04-22 Wyeth Compositions, organisms and methodologies employing a novel human kinase
US8043622B2 (en) 2002-10-08 2011-10-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
JP2006514544A (ja) * 2002-10-10 2006-05-11 ワイス 新規ヒトキナーゼを使用する組成物、有機体および方法
CA2501752A1 (en) * 2002-10-10 2004-04-22 Wyeth Compositions, organisms and methodologies employing a novel human kinase
AU2003301348A1 (en) * 2002-10-18 2004-05-04 Wyeth Compositions and methods for diagnosing and treating autoimmune disease
EP1554385A2 (en) * 2002-10-24 2005-07-20 Wyeth Calcineurin-like human phoshphoesterase
MXPA05004588A (es) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
EP1588142A4 (en) * 2002-11-21 2007-10-31 Wyeth Corp METHOD FOR DIAGNOSIS OF RCC AND OTHER SOLID TUMORS
US7297525B2 (en) 2002-11-27 2007-11-20 Wyeth Composition employing a novel human kinase
US9388427B2 (en) 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
US7803365B2 (en) * 2002-12-02 2010-09-28 Biovec, Llc Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
CA2511907A1 (en) * 2003-01-06 2004-07-22 Wyeth Compositions and methods for diagnosing and treating colon cancers
US20050266409A1 (en) * 2003-02-04 2005-12-01 Wyeth Compositions and methods for diagnosing, preventing, and treating cancers
CA2515916A1 (en) * 2003-02-25 2004-09-10 Biovec B.V. Therapeutic applications of thrombomodulin gene via viral and non-viral vectors
WO2004076639A2 (en) * 2003-02-26 2004-09-10 Wyeth Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
WO2005003164A2 (en) * 2003-03-04 2005-01-13 Wyeth Compositions and methods for diagnosing and treating asthma or other allergic or inflammatory diseases
US20040198640A1 (en) * 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
US20050119210A1 (en) * 2003-05-20 2005-06-02 Xiaobing Be Compositions and methods for diagnosing and treating cancers
US8071652B2 (en) * 2003-08-21 2011-12-06 The Board Of Regents Of The University Of Texas System Method of treating irritable bowel syndrome
US7615539B2 (en) 2003-09-25 2009-11-10 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
EP1697511A4 (en) * 2003-12-11 2007-11-21 Vaxdesign Corp IMMUNOTHERAPY COMPOSITIONS, METHODS FOR PREPARING AND USING THE SAME
EP2248895B8 (en) 2003-12-19 2016-09-21 Autotelic LLC Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent
EP1720568A2 (en) 2004-02-19 2006-11-15 Coley Pharmaceutical Group, Inc. Immunostimulatory viral rna oligonucleotides
EP1568383A3 (en) 2004-02-27 2005-11-16 Antisense Pharma GmbH Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
KR101147147B1 (ko) * 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
CN1989439B (zh) 2004-05-06 2010-12-29 美国政府健康及人类服务部 治疗葡萄膜炎的方法以及组合物
WO2007026190A2 (en) 2004-07-18 2007-03-08 Csl Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
EP1789070B1 (en) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in neuronal function
KR100721928B1 (ko) 2004-11-05 2007-05-28 주식회사 바이오씨에스 ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
US7935811B2 (en) 2004-11-22 2011-05-03 Dharmacon, Inc. Apparatus and system having dry gene silencing compositions
US7923206B2 (en) 2004-11-22 2011-04-12 Dharmacon, Inc. Method of determining a cellular response to a biological agent
US7923207B2 (en) 2004-11-22 2011-04-12 Dharmacon, Inc. Apparatus and system having dry gene silencing pools
US7939490B2 (en) * 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
US9809824B2 (en) 2004-12-13 2017-11-07 The United States Of America, Represented By The Secretary, Department Of Health And Human Services CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
FR2881143B1 (fr) 2005-01-27 2010-12-17 Librophyt Systeme de production de terpenoides dans les plantes
US20100130425A1 (en) 2005-09-09 2010-05-27 Oregon Health & Science University Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
EP1981902B1 (en) 2006-01-27 2015-07-29 Biogen MA Inc. Nogo receptor antagonists
US20080045473A1 (en) 2006-02-15 2008-02-21 Coley Pharmaceutical Gmbh Compositions and methods for oligonucleotide formulations
US8252755B2 (en) 2006-09-22 2012-08-28 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
PT2078080E (pt) 2006-09-27 2015-09-18 Coley Pharm Gmbh Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
AU2007353317B2 (en) * 2006-11-15 2012-09-06 Eli Lilly And Company Methods and compositions for treating influenza
ES2544484T3 (es) 2007-05-18 2015-08-31 Adiutide Pharmaceuticals Gmbh Análogos de oligonucleótidos modificados con fosfato con actividad inmunoestimulante
KR20100068422A (ko) 2007-10-09 2010-06-23 콜리 파마슈티칼 게엠베하 변경된 당 잔기를 함유하는 면역자극성 올리고뉴클레오티드 유사체
WO2009060281A2 (en) 2007-11-06 2009-05-14 Coley Pharmaceutical Gmbh Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
US7845686B2 (en) * 2007-12-17 2010-12-07 S & B Technical Products, Inc. Restrained pipe joining system for plastic pipe
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
US8222225B2 (en) 2008-05-21 2012-07-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating pneumoconiosis with oligodeoxynucleotides
US8552165B2 (en) 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
SG171829A1 (en) 2008-12-09 2011-07-28 Coley Pharm Group Inc Immunostimulatory oligonucleotides
MX2011006077A (es) 2008-12-09 2011-09-01 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige.
US20120052088A1 (en) 2009-04-30 2012-03-01 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
EP2340308B1 (en) 2009-07-30 2014-12-24 ISARNA Therapeutics GmbH Combination of dacarbazine and an inhibitor of the TGF-beta system
NZ618391A (en) 2009-07-30 2015-07-31 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
WO2011027257A2 (en) 2009-09-03 2011-03-10 Pfizer Vaccines Llc Pcsk9 vaccine
WO2011109422A2 (en) 2010-03-02 2011-09-09 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment of cancer
SI2575878T1 (sl) 2010-05-28 2018-12-31 Zoetis Belgium S.A. Cepiva, ki obsegajo holesterol in cpg kot edine molekule, ki nosijo adjuvans
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
EP3260540A1 (en) 2010-11-12 2017-12-27 The General Hospital Corporation Polycomb-associated non-coding rnas
EP2680883B1 (en) 2011-03-02 2018-09-05 Pfizer Inc Pcsk9 vaccine
EP2726402A1 (en) 2011-07-01 2014-05-07 President and Fellows of Harvard College Method for forming nanoparticles having predetermined shapes
US9580708B2 (en) 2011-09-14 2017-02-28 Rana Therapeutics, Inc. Multimeric oligonucleotides compounds
WO2013148186A1 (en) 2012-03-26 2013-10-03 President And Fellows Of Harvard College Lipid-coated nucleic acid nanostructures of defined shape
AU2013252785B2 (en) 2012-04-27 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of CpG oligonucleotides co-formulated with an antibiotic to accelarate wound healing
SI2844282T1 (sl) 2012-05-04 2019-08-30 Pfizer Inc. S prostato povezani antigeni in na cepljenju osnovan imunoterapevtski režim zdravljenja
US10174315B2 (en) 2012-05-16 2019-01-08 The General Hospital Corporation Compositions and methods for modulating hemoglobin gene family expression
KR20160074368A (ko) 2012-05-16 2016-06-28 라나 테라퓨틱스, 인크. Utrn 발현을 조절하기 위한 조성물 및 방법
AU2013262709A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
DK2850186T3 (en) 2012-05-16 2019-04-08 Translate Bio Ma Inc COMPOSITIONS AND PROCEDURES FOR MODULATING SMN GENFAMILY EXPRESSION
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
CN104583401A (zh) 2012-05-16 2015-04-29 Rana医疗有限公司 用于调节atp2a2表达的组合物和方法
KR101835401B1 (ko) 2012-07-13 2018-03-08 신 니뽄 바이오메디칼 라보라토리즈, 엘티디. 키랄 핵산 어쥬번트
AU2013315225B2 (en) 2012-09-14 2018-11-08 Translate Bio Ma, Inc. Multimeric oligonucleotide compounds
WO2014201245A1 (en) 2013-06-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
WO2015023941A1 (en) 2013-08-16 2015-02-19 Rana Therapeutics, Inc. Oligonucleotides targeting euchromatin regions of genes
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
US9897597B2 (en) 2014-04-23 2018-02-20 Children's Medical Center Corporation High-throughput structure determination using nucleic acid calipers
WO2016070060A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
EP3240801B1 (en) 2014-12-31 2021-01-20 Checkmate Pharmaceuticals, Inc. Combination tumor immunotherapy
WO2016130943A1 (en) 2015-02-13 2016-08-18 Rana Therapeutics, Inc. Hybrid oligonucleotides and uses thereof
US10900036B2 (en) 2015-03-17 2021-01-26 The General Hospital Corporation RNA interactome of polycomb repressive complex 1 (PRC1)
WO2016183370A1 (en) 2015-05-13 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Synthetic immunosuppressive oligodeoxynucleotides reduce ischemic tissue damage
WO2016183371A1 (en) 2015-05-13 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for the treatment or prevention of ischemic tissue damage
WO2017192874A1 (en) 2016-05-04 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Albumin-binding immunomodulatory compositions and methods of use thereof
CA3084439A1 (en) 2017-12-07 2019-06-13 Massachusetts Institute Of Technology Single cell analyses
WO2019160866A2 (en) 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
KR20210006905A (ko) 2018-04-09 2021-01-19 체크메이트 파마슈티칼스 바이러스-유사 입자 내로의 올리고뉴클레오타이드의 포장
WO2021154745A1 (en) 2020-01-27 2021-08-05 Oregon State University Gonorrhea subunit vaccine
US20240189410A1 (en) 2022-12-13 2024-06-13 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4237224A (en) * 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4321365A (en) * 1977-10-19 1982-03-23 Research Corporation Oligonucleotides useful as adaptors in DNA cloning, adapted DNA molecules, and methods of preparing adaptors and adapted molecules
GB2068971B (en) * 1980-01-30 1983-06-08 Searle & Co Recombinant dna techniques
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4469863A (en) * 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
AU568067B2 (en) * 1981-10-23 1987-12-17 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and methods of making same
US5023243A (en) * 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same

Also Published As

Publication number Publication date
DE3280400D1 (de) 1992-06-04
WO1983001451A1 (en) 1983-04-28
DK288183D0 (da) 1983-06-22
DK288183A (da) 1983-06-22
CA1208147A (en) 1986-07-22
IE58009B1 (en) 1993-06-16
EP0092574A4 (en) 1984-02-09
IE822547L (en) 1983-04-23
JPH08294393A (ja) 1996-11-12
JP2547714B2 (ja) 1996-10-23
US7285537B1 (en) 2007-10-23
EP0092574A1 (en) 1983-11-02
IT1206311B (it) 1989-04-14
JPS58501771A (ja) 1983-10-20
EP0092574B1 (en) 1992-04-29
AU9124382A (en) 1983-05-05
ATE75483T1 (de) 1992-05-15
AU568067B2 (en) 1987-12-17
US5919619A (en) 1999-07-06
IL67053A (en) 1997-07-13

Similar Documents

Publication Publication Date Title
IT8223872A0 (it) Agente terapeutico a base di oligonucleotide e metodi per laproduzione dello stesso.
FI822770A0 (fi) Bensazepin-2-oner, foerfarande foer deras framstaellning, farmaceutiska preparat innehaollande dessa foereningar samt deras terapeutiska anvaendning
NO822860L (no) Acylfosfinoksyder, samt anvendelse derav.
FI822813A7 (fi) Uudet farmaseuttiset seokset.
FI913899A0 (fi) Terapeutiska aerosolblandningar.
IT8019201A0 (it) Agente di pulitura.
IT8521619A0 (it) Apparato per profilatura.
DK570182A (da) Budbringer-rna samt fremstilling og anvendelse deraf
NL190188C (nl) Verwarmingsstaaf en werkwijze voor de vervaardiging daarvan.
IT8321018A0 (it) Agente immunomodulante.
IT8219339A0 (it) Cromani sostituiti ad azione farmaceutica.
IT8521097A0 (it) Agente gelificante per celle.
FI881651A0 (fi) Terapeutiska nukleosider.
IT8219704A0 (it) Agente di proliferazione per bifidobatteri.
IT8219308A0 (it) Piegatrice. macchina combinata raddrizzatrice e
IT8124621A0 (it) Agente per la riduzione del colesterolo.
FI904854A0 (fi) Terapeutiska nukleosider.
DE3865417D1 (de) Vinylester-latizes.
FI902973A0 (fi) Magnetfaeltsgenerator foer terapeutiska aendamaol.
IT8221898A0 (it) Procedimento di tempra a rifusione.!
FI881216A0 (fi) Terapeutiska nukleosider.
NO830294L (no) Medikamentinhalator.
IT8223097A0 (it) 5-fenossifenil-tetraidro-1,3,5-tiadiazin-4-oni.
IT8719588A0 (it) Agente anti-psoriasi.
FI854858A0 (fi) 1,4-dihydropyridinderivat, deras framstaellning och farmaceutiska preparat innehaollande desamma.

Legal Events

Date Code Title Description
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19971029